Effect of glucoseinsulinpotassium on hyperlactataemia inpatients undergoing valvular heart surgery: A randomised controlled study Un Roh, Go; Shim, Jae Kwang; Song, Jong Wook; Kang, Hye Min; Kwak, Y
Un Roh, Go; Shim, Jae Kwang; Song, Jong Wook; Kang, Hye Min; Kwak, Young Lan
BACKGROUND: Hyperlactataemia represents oxygen imbalance in the tissues and its occurrence during cardiac surgery is associated with adverse outcomes. Glucose–insulin–potassium (GIK) infusion confers myocardial protection against ischaemia-reperfusion injury and has the potential to reduce lactate release while improving its clearance.
OBJECTIVES: The objective of this study is to compare the effect of GIK on the incidence of hyperlactataemia in patients undergoing valvular heart surgery.
DESIGN: A randomised controlled study.
SETTING: Single university teaching hospital.
PATIENTS: One hundred and six patients scheduled for elective valvular heart surgery with at least two of the known risk factors for hyperlactataemia.
INTERVENTION: Patients were randomly allocated to receive either GIK solution (insulin 0.1 IU kg−1 h−1and an infusion of 30% dextrose and 80 mmol l−1potassium at 0.5 ml kg−1 h−1) or 0.9% saline (control) throughout surgery.
MAIN OUTCOME MEASURES: The primary outcome was the incidence of hyperlactataemia (lactate ≥4 mmol l−1) during the operation and until 24 h after the operation. Secondary outcomes included haemodynamic parameters, use of vasopressor or inotropic drugs, and fluid balance until 24 h postoperatively. Postoperative morbidity endpoints were also assessed.
RESULTS: The incidences of hyperlactataemia were similar in the groups (32/53 patients in each of the control and GIK groups,P > 0.999). There were no intergroup differences in haemodynamic parameters, use of vasopressor and inotropic drugs, or fluid balance. The incidences of postoperative morbidity endpoints were similar in both groups.
CONCLUSION: Despite its theoretical advantage, GIK did not provide beneficial effects in terms of the incidence of hyperlactataemia or outcome in patients undergoing valvular heart surgery.
TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT01825720.
European Journal of Anaesthesiology:
copyright© 版权所有,未经许可不得复制、转载或镜像
京ICP证120392号 京公网安备110105007198 京ICP备10215607号-1 (京)网药械信息备字(2022)第00160号